Denali Therapeutics Inc. (DNLI) Operating margin 2018–2023
Denali Therapeutics Inc. (DNLI) operating margin by fiscal year — reported operating income divided by reported revenue.
-59.5%FY2023 · since FY2018: -35.9% → -59.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -59.5% | +264.8 pp |
| FY2022 | -324.3% | +283.5 pp |
| FY2021 | -607.8% | -626.5 pp |
| FY2020 | 18.7% | +828.7 pp |
| FY2019 | -810.0% | -774.1 pp |
| FY2018 | -35.9% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More DNLI financial trends
DNLI RevenueDNLI Net incomeDNLI Net marginDNLI Gross profitDNLI Gross marginDNLI Operating incomeDNLI Operating cash flowDNLI Free cash flowDNLI Capital expendituresDNLI Return on equityDNLI Stock buybacksDNLI Dividends paidDNLI Total assetsDNLI Total liabilitiesDNLI Shareholders’ equityDNLI overview →